Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Ties Increased Transfusions To ESA Scrutiny in NCD Review Request

Executive Summary

Amgen has released an internally generated analysis of data that draws a causal link between an increase in blood transfusions and the heightened scrutiny erythropoiesis-stimulating agents have received this year
Advertisement

Related Content

Amgen Plans Seven ESA Risk Studies After Latest Safety Update To Labeling
Amgen Plans Seven ESA Risk Studies After Latest Safety Update To Labeling
Medicare ESA Coverage Will Not Experiment With Clinical Trial Approach
EPO Scathed But Survives ODAC Challenge; Cmte. Calls For Additional Trials
Amgen, J&J Barred From Marketing Procrit, Aranesp Chemo-Anemia Benefit
Advertisement
UsernamePublicRestriction

Register

PS049012

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel